Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors

Drugs of Today

Volumn 51, Issue 4, 2015, Pages 223-229

  Scott, A J ^a   Messersmith, W A ^a   Jimeno, A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Antiangiogenic drugs; Apatinib; Solid tumor; VEGF; VEGFR 2

Indexed keywords

ANGIOGENESIS INHIBITOR; APATINIB; BIOLOGICAL MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; PYRIDINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ANEMIA; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; VASCULARIZATION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84929086130     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2015.51.4.2320599     Document Type: Article

References (15)

1. Ferrara, N., Gerber, H.P., LeCouter, J. The biology of VECF and its receptors. Nat Med 2003, 9(6): 669-76.
2. Ferrara, N. The role of VECF in the regulation of physiological and pathological angiogenesis. EXS 2005 (94): 209-31.
3. Longo, R., Gasparini, G. Challenges for patient selection with VECF inhibitors. Cancer Chemother Pharmacol 2007, 60(2): 151-70.
4. Tian, S., Quan, H., Xie, C. et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011, 102(7): 1374-80.
5. Mi, Y.J., Liang, Y.J., Huang, H.B. et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 2010, 70(20): 7981-91.
6. Tong, X.Z., Wang, F, Liang, S. et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol 2012, 83(5): 586-97.
7. Ding, J., Chen, X., Gao, Z. et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos 2013, 41(6): 1195-210.
8. Li, J., Zhao, X., Chen, L. et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 2010, 10: 529.
9. Li, J., Qin, S., Xu, J. et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013, 31(26): 3219-25.
10. Hu, X., Zhang, J., Xu, B. et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily preheated patients with metastatic triple-negative breast cancer. Int J Cancer 2014, 135(8): 1961-9.
11. Hu, X., Cao, J., Hu, W. et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer 2014, 14: 820.
12. Zhang, L.S., Huang, C, et al. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced non-squamous non-small cell lung (NSCLC) after two previous treatment regimens. J Clin Oncol [ASCO Annu Meet (Jun 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 7548.
13. Qin, S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol [ASCO Annu Meet (May 30-Jun 3, Chicago) 2014] 2014, 32(Suppl.): Abst 4003.
14. Fan, M., Zhang, J., Wang, Z. et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy Breast Cancer Res Treat 2014, 143(1): 141-51.
15. Van Cutsem, E., de Haas, S., Kang, Y.K. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012, 30(17): 2119-27.